ACADIA Pharmaceuticals

ACADIA Pharmaceuticals

World Rank (Aug-2026)
3702
Market Cap (Aug-2026)
4.866 Billion USD
Market Cap (Mar-08-2026)
3.778 Billion USD
World Rank (Jan-05-2024)
2,957
Market Cap (Jan-05-2024)
4.917 Billion USD
World Rank (Jul-30-2023)
3,125
Market Cap (Jul-30-2023)
4.723 Billion USD
World Rank (Jan-07-2022)
4,217
Market Cap (Jan-07-2022)
3.631 Billion USD
World Rank (Jan-01-2021)
1,913
Market Cap (Jan-01-2021)
8.499 Billion USD
Headquarters Country
USA
Top Healthcare Companies in USA
Top Pharmaceutical Companies in USA
Nasdaq / NYSE Code
ACAD
Employee Count
513
Employee Count as of Date
As on 2022
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
1,072 Million USD
Annual Operating Income in USD
105 Million USD
Annual Net Income in USD
391 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
1,564 Million USD
Total Liabilities in USD
337 Million USD
Total Equity in USD
1,227 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Pharmaceutical
HealthCare Products
Biotechnology
Company Website
ACADIA PHARMACEUTICALS INC
Wikipedia
Wikipedia
Yahoo
Yahoo @ Nasdaq
Company Profile

Acadia Pharmaceuticals is a Healthcare and Pharmaceutical company. The company is of food and drug administration for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Around 8 million people in the United States are living with dementia and studies suggest that approximately 30% of people with dementia, 2.4 million people, experience dementia-related hallucinations and delusion. The headquarters is in USA.

Annual Results Summary

ACADIA PHARMACEUTICALS - Annual Results Summary - in Million USD

Year Ending:Total RevenueOperating IncomeNet Income
Dec-2022517-223 (Loss)-215 (Loss)
Dec-2021484 -170 (Loss)-167 (Loss)
Dec-2020441.8(286.6) (Loss)(281.6) (Loss)
Dec-2019339.1(246.5) (Loss)(235.3) (Loss)
Dec-2018223.8(247.4) (Loss)(245.2) (Loss)
Dec-2017124.9(292.4) (Loss)(289.4) (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 587 Million USD.

Total Liabilities as on Dec-2022 was 187 Million USD.

Total Equity as on Dec-2022 was 400 Million USD.

Founded Year
1993
IPO Year
1985
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share